A recently developed stable isotope dilution liquid chromatography-multiple reaction/mass spectrometry method to quantify focal adhesion kinase (FAK) 
[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530). Phosphorylation of FAK at Tyr 576 /Tyr 577 was inhibited by AZD0530 in a dose-dependent manner both in cell culture and in vitro. However, there was a substantial difference in the ability of AZD0530 to inhibit Src that was constitutively activated in a cellular context (IC 50 ϭ 2.12 M) compared with the isolated enzyme (IC 50 ϭ 0.14 M).
When normal MEFs and Y
529 FSrc-expressing MEFs were treated with pervanadate (a global phosphatase inhibitor), pTyr 576 /pTyr 577 -FAK accounted for almost 60% of the total FAK present in the cells. This suggests that activation loop phosphorylation is regulated by tyrosine phosphatases. These results confirm that FAK phosphorylation is a useful biomarker of Src inhibition in vivo. The accuracy and specificity of stable isotope dilution liquid chromatography-mass spectrometry methodology offers significant advantages over current immunochemical approaches for monitoring Src activity.
The Src family kinases comprise 11 structurally related, membrane-associated, nonreceptor protein tyrosine kinases including cellular-Src (c-Src), c-Yes, Fyn, Lyn, Hck, Blk, Brk, Fgr, Frk, Srm, and Yrk (Summy and Gallick, 2003; Yeatman, 2004; Meyn and Smithgall, 2008) . Although most Src family members are expressed primarily in cells of hematopoietic origin, c-Src, c-Yes, and Fyn are expressed more ubiquitously with high levels of expression in some epithelial tissues, platelets, and neurons (Thomas and Brugge, 1997) . They are rarely mutated in human tumors but are overexpressed or activated in a variety of tumors, including colon, breast, pancreatic, bladder, head and neck, ovarian, and brain (Summy and Gallick, 2003) . Although Src is a proto-oncogene, its association with FAK (another nonreceptor tyrosine kinase) is critical for the formation of metastases (Basson, 2008) . Therefore, Src is an emerging therapeutic target to prevent metastases from occurring (Sawyer, 2004; Rucci et al., 2008) . Preclinical experiments indicate that small-molecule inhibitors of Src block tumor growth, metastasis, and angiogenesis (Hiscox and Nicholson, 2008) . The binding of Src to FAK results in phosphorylation of FAK at multiple residues, critical among them being the Tyr 576 and Tyr 577 sites located on FAK's kinase activation loop ( Fig. 1) (Calalb et al., 1995; Owen et al., 1999; Ruest et al., 2000; Ciccimaro et al., 2006) . In a global phosphotyrosine proteome analysis, FAK Tyr 576 emerged as the most readily detected Src target in cultured nontransformed fibroblasts (Luo et al., 2008) . The interplay of Src and FAK is a vital convergence point, integrating signals of cell growth, survival, and migration, making the pharmacological inhibition of Src a unique target for cancer drug therapy (Rucci et al., 2008) . The use of recently developed orally available Src kinase inhibitors to reduce tumor growth shows particular promise for preventing metastasis in vivo (Summy et al., 2005; Ischenko et al., 2007; Jallal et al., 2007; Shor et al., 2007; Park et al., 2008) . Although the inhibition of Src in the treatment of cancer represents an important molecular target, there remains a need to develop validated biomarkers to monitor the efficacy of this approach. It has been very challenging to accurately assess the function of Src in intact cells because of the complex signal transduction pathways that are involved (Kansra et al., 2005; Mishra et al., 2005; Ozawa et al., 2008; Vultur et al., 2008) . Most current approaches use biomarkers for Src activity that rely on quantifying the effects of an isolated enzyme acting on a synthetic peptide substrate (Hennequin et al., 2006) or the use of immunoprecipitation of a downstream protein target followed by Western blot analysis (Summy et al., 2005) .
Several studies have been conducted to identify biomarkers of Src activity after treatment of cells with Src inhibitors including those using bosutinib (SKI-606) (Vultur et al., 2008) and AZD0530 (Serrels et al., 2006) . These studies were able to correlate tyrosine phosphorylation of Src substrates with drug treatment; autophosphorylation of Src in the former, and paxillin and FAK phosphorylation in the latter. However, they were limited to conducting relative quantification, and so normalization of phosphorylation to the amount of residual unphosphorylated protein was not possible. Therefore, differences in protein expression, immunoprecipitation efficiency, or other intersample variability factors could not be addressed. FAK phosphorylation on Tyr 576 / Tyr 577 most accurately reflects Src activity (Ciccimaro et al., 2006) , and so we have developed a new LC-MRM/MS method that quantifies FAK phosphorylation as a robust biomarker of Src activity in vitro, in cell culture, and ultimately in vivo (E. Ciccimaro, S. K. Hanks, and I. A. Blair, submitted) .
This new method has made it possible to accurately determine the absolute amounts of FAK phosphorylation that occurs after Src inhibition in vitro and in cell culture with increasing concentrations of the Src inhibitor AZD0530 (Hennequin et al., 2006) . Furthermore, because the technique is self-normalizing, problems arising from intersample differences in FAK expression levels, immunoprecipitation efficiency, and assay sensitivity were eliminated.
Materials and Methods

Materials.
The gene for human FAK (protein tyrosine kinase 2 ␣) in the Gateway entry vector pENTER221 was from Invitrogen (Carlsbad, CA). The pDEST26 and pEXP1 plasmids, nickel-chelating resin (Probond), the cell-free expression system, and recombinant full-length c-Src and FAK were also from Invitrogen. Dialysis cassettes were from Pierce Biotechnology (Rockford, IL). Anti-FAK beads (clone 4.47, agarose conjugate beads) were from Millipore (Billerica, MA). Protease inhibitors were from Roche Applied Sciences (Indianapolis, IN). The Src inhibitor AZD0530 was a kind gift from AstraZeneca (Macclesfield, Cheshire, UK). The autosampler was a CTC pal from Leap Technologies (Carrboro, NC), whereas the LC pump was an ExpressLC100 system from Eksigent Technologies (Dublin, CA). LC-grade water and acetonitrile were from Burdick and Jackson (Muskegon, MI), whereas Suprapur formic acid was from EMD Chemical (Gibbstown, NJ). The reverse-phase column (50 ϫ 1 mm internal diameter) was custom-made using extended C18 (300 Å, 3.5 m) by Agilent Technologies (Santa Clara, CA). All standard peptides were synthesized and quantified using amino acid analysis by AnaSpec, Inc. (San Jose, CA).
Cell 15 N]leucine was produced using the expressway cell-free expression system, supplied with heavy isotope-labeled amino acids, similar to published techniques (Torizawa et al., 2004; Hanke et al., 2008 15 N]FAK was mixed 1:1 with a denaturing buffer consisting of 6 M urea, 2 M thiourea, and 10 mM dithiothreitol and heated at 37°C for 30 min. After heating, the solution containing denatured [ 13 C
15 N]FAK was dialyzed for 6 h at 4°C against oxidizing dialysis buffer (1 mM oxidized glutathione, 40 mM Tris-HCl, pH 7.5, 150 mM NaCl, 270 mM sucrose, 100 M EGTA, 100 M Na 3 VO 4 , and 0.03% Brij-35) using a 10,000 molecular weight cutoff filter dialysis cassette. After 6 h, the dialysis buffer was replaced, and dialysis was allowed to continue for an additional 6 h. The refolded and bufferexchanged [ 13 C 15 N]FAK was then split into portions, and each portion was adjusted to contain 1 mM ATP, 1ϫ kinase buffer, and recombinant Src (33 nM full-length recombinant c-Src). After incubation at 37°C for 30 min, all portions were pooled and stored at Ϫ80°C. Both full-scanning LC/tandem mass spectrometry and LC-MRM/MS were used to ascertain the extent of Tyr 576 /Tyr 577 phosphorylation on [ 13 C 15 N]FAK. In Vitro Src Inhibition Assay. Recombinant full-length human c-Src (12 nM) was incubated in kinase buffer (25 mM TrisHCl, pH 7.5, 5 mM ␤-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 3 , and 10 mM MgCl 2 ) containing vehicle (0.1% DMSO) or AZD0530 (0.01, 0.1, 1, and 10 M) at 4°C for 30 min. After incubation, samples were prepared with recombinant human FAK (120 nM) and 1 mM ATP except for the vehicle (ϪATP) sample, O [0.1:20 (v/v) ] with 0.1% formic acid. The mobile phase was diverted to waste for the first 5 min under these conditions to remove salts, after which the flow rate was reduced to 14 l/min, and peptides were eluted over a 30-min gradient from 0 to 40% buffer containing acetonitrile/H 2 O [19:1 (v/v)] with 0.1% formic acid. An LTQ mass spectrometer (Thermo Fisher Scientific, San Jose, CA) was operated in the positive electrospray ionization mode with helium as the collision gas. Cell Culture. MEF populations expressing murine Src Y 529 F or vector-only were used (Brabek et al., 2004) . Cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, and penicillin/streptomycin. Cultures were kept lower than 90% confluence on 100-mm culture dishes until harvesting, at which point they were allowed to grow to full confluence. Pervanadate treatment was conducted by exposing cell monolayers to 3 mM H 2 O 2 /1 mM Na 3 VO 4 for 10 min before harvesting. Src inhibition using AZD0530 was performed by incubating cells in complete Dulbecco's modified Eagle's medium (as above) containing either vehicle (0.1% DMSO) or AZD0530 (0.01, 0.1, 1, 10, or 50 M) for 3 or 12 h.
Analysis of FAK Activation Loop Phosphorylation Status
Immunoprecipitation Recovery of FAK from Cell Lysates. Recombinant FAK (258.8 nM) and c-Src (12.8 nM) in a total volume of 200 l was incubated in the presence of ATP (1 mM) at 37°C for 5 min. The reaction mixture was then heated to 70°C for 10 min. A 10-l portion of this reaction mixture together with 12 l of [ 13 C
15 N]FAK solution were added to a lysing dish of FAK Ϫ/Ϫ MEFs, or a 10-l portion of this reaction together with 6 l of the [ 13 C
15 N]FAK solution were added to two lysing dishes, and pooled. Immunoprecipitation was conducted as described above. In parallel, 12 l of heat-inactivated [ 13 C 15 N]FAK solution was mixed with a 10-l portion of the in vitro kinase reaction in a vial. After the elution of FAK from the immune complex, 13 C 15 N peptide standards were added, the mixtures were digested with trypsin, and the digests were analyzed by LC-MRM/MS as described above.
Analysis of FAK Activation Loop Phosphorylation after Immunoprecipitation. 
Results
In Vitro Inhibition of Src. To evaluate FAK inhibition by AZD0530 in a controlled setting, Src was inhibited by the drug in vitro and then incubated with recombinant FAK. values recorded for FAK reacted with vehicle-treated Src in the presence of ATP correspond to maximal kinase activity under these experimental conditions, and therefore, all AZD0530-inhibited Src results are presented as the percentage of maximal activity relative to these amounts.
Analysis of the unmodified activation loop region (YMED-STYYK) showed the activity of Src under assay conditions was not significantly inhibited by 0.01 M AZD0530. A 10% reduction in Src activity to 89.9% of the maximum was seen in the 0.1 M AZD0530 treatment, with further reductions to 44.7 and 4.9% of maximum at 1 and 10 M treatment with AZD0530, respectively (Fig. 2A) . The prevention of Src's ability to modify the activation loop region coincided with a dose-dependent decrease in the production of FAK monopTyr 576 and bis-pTyr 576 pTyr 577 activation loop forms. At 0.1 M, AZD0530 reduced the bis-phosphorylation of the activation loop to 64.8% of the maximal level; however, this was concurrent with an increase in the amount of the monopTyr 576 form to 34.0% greater than the maximum. BispTyr 576 /pTyr 577 was further reduced with 1 and 10 M AZD0530 to 12.5 and 0.4%, respectively. Mono-phosphorylation at Tyr 576 was not inhibited at 1 M but was reduced to 12.6% of the maximal level at a concentration of 10 M AZD0530 (Fig. 2B) . A best-fit IC 50 value using the quantification of bis-phosphorylated FAK activation loop domain was found to be 0.14 M (95% confidence 0.07-0.30 M) (Fig. 2C) .
Immunoprecipitation Recovery of FAK from Cell Lysates. To confirm that our methodology correctly quantified FAK phosphorylation after protein immunoprecipitation, we measured the amount of FAK phosphorylation on a known amount of recombinant FAK spiked into and then immunoprecipitated from a FAK-null cell lysate. The amounts of unmodified, pTyr 576 , and pTyr 576 /pTyr 577 FAK present in the kinase reaction mixture before the immunoprecipitation were 0.707 (Ϯ 0 (Fig. 3) . The total amount of FAK activation loop peptides in the Y 529 FSrc-expressing MEFs was 0.836 (Ϯ 0.027) pmol (Fig. 3) . These values were obtained by using calculated immunoprecipitation recoveries of 25% for unmodified FAK and 14% for phosphorylated FAK in the Y 529 FSrc-expressing MEFs. The average total FAK amount (corrected for losses during immunoprecipitation) was 1.5 pmol/plate (i.e., 187.5 ng of FAK/2.47 mg of total protein). (Fig. 4) 1.160 (Ϯ 0.047) pmol, respectively (Fig. 6) . 576 -FAK amounts to 112.5% (Ϯ 9.0%) of maximum. At this treatment concentration, the amount of unmodified FAK was approximately 100% of the maximal level at 101.8% (Ϯ 10.9%). Treatment with 10 M AZD0530 further reduced pTyr 576 /pTyr 577 -FAK amounts to 5.9% (Ϯ 8.3%), whereas it reduced pTyr 576 -FAK amounts to 76.4% (Ϯ 14.0%) of maximum. Concurrently, this dose increased the amount of unmodified FAK, and decreased the amount of phosphorylated-FAK activation loop to 47.5% (Ϯ 4.5%) of maximum. At 50 M AZD0530, no pTyr 576 / pTyr 577 -FAK was detected, and pTyr 576 -FAK was reduced to only 14.8% (Ϯ 5%) of maximum. At this dose, nearly all FAK recovered was in the unmodified form, reducing the amount of modified forms to 8.7% (Ϯ 3.0%) of their maximum levels (Figs. 7, A and B) . A best-fit IC 50 value using the quantification of bis-phosphorylated FAK activation loop was found to be 2.12 M (95% confidence 0.74-6.07 M) (Fig. 7C) .
Analysis of FAK Activation Loop Phosphorylation in MEFs after Inhibition with Pervanadate. The ability of
Analysis of a Biomarker of Src
Discussion
Inhibition of Src with AZD0530 in vitro prevented modification on the activation loop region as reflected in both the amount of unmodified FAK preserved and the amount of pTyr 576 -FAK and pTyr 576 /pTyr 577 -FAK produced. It is noteworthy that the dose-response curve obtained for pTyr 576 -FAK showed an initial increase at 0.1 M AZD0530 (Fig. 2B) . This result can be explained by the prevention of Src from converting the monophosphorylated activation loop domain into the bis-phosphorylated form at this concentration without preventing Tyr 576 -FAK phosphorylation. Concurrently, there was a dose-dependent decrease in pTyr 576 /pTyr 577 -FAK with increasing AZD0530 concentrations with an IC 50 value of 0.14 M (Fig. 2C) . The initial description of AZD0530 inhibition of Src activity toward the poly(GluTyr) peptide by Hennequin et al. (2006) found an IC 50 value of 0.0027 (Ϯ 0.0005) M. The discrepancy between IC 50 values can be explained by differences between assay methodologies. Both Src concentrations and ATP concentrations could alter the amount of inhibitor required to inhibit Src activity, because AZD0530 will compete for binding at the ATP binding pocket of Src proteins. Assay conditions in the present study involved the use of 12 nM Src and 1 mM ATP, whereas studies by other investigators used 2 nM Src and 0.04 mM ATP (Ple et al., 2004) . The differences in assay conditions reflect the goal of the respective experiments. Our studies involve Src inhibition in cell culture systems; therefore, we chose to use 1 mM ATP as found in cell models (Beis and Newsholme, 1975) . Conversely, the goal of previous studies was to develop small compound inhibitors of Src, which required the assay to be sensitive to even weakly inhibiting compounds (Hennequin et al., 2006) .
Two cell models were used in the present study: vector control MEFs that expressed only the endogenous Src-family kinases and oncogenic MEFs that expressed the Y 529 FSrc variant (Brabek et al., 2004) . The Tyr 529 -to-Phe 529 amino acid substitution in Src results in a constitutively active form as a result of the inability of the kinase to achieve its normal autoinhibited and inactive conformation. Y 529 FSrc extensively phosphorylates multiple substrate proteins (including FAK), resulting in cellular transformation (Cooper et al., 1986; Okada and Nakagawa, 1989; Brabek et al., 2004; Luo et al., 2008 (Fig. 3) . This indicates that a significant fraction of total FAK exists in a subcellular locale sequestered from the action of Src and/or that Tyr 577 is dephosphorylated by a phosphatase at a greater rate than Src phosphorylates it. To address these issues, the consequences of global tyrosine phosphatase inhibition using pervanadate were explored.
Pervanadate is known to broadly inhibit tyrosine phosphatases, thus dramatically increasing the extent of tyrosine phosphorylation on multiple proteins and, more relevantly, increasing the extent that FAK Tyr 576 and Tyr 577 are phosphorylated (Maa and Leu, 1998) . Pervanadate treatment of either normal or Y 529 FSrc-expressing MEFs led to the majority of total FAK in the cell existing as the pTyr 576 /pTyr 577 -FAK form, with approximately 0.4 to 0.5 pmol/pmol of total FAK, leaving only 0.1 to 0.2 pmol/pmol of total FAK in the unmodified form, regardless of which form of Src was present (Fig. 5) . After the 10-min pervanadate treatment, almost 20% of FAK remained in the unmodified form, indicating that a portion of the cellular protein was resistant to phosphorylation by Src; however, almost 60% of FAK existed as the pTyr 576 /pTyr 577 -FAK form, suggesting that activation loop phosphorylation is potently regulated by a tyrosine phosphatase(s). We considered the possibility that FAK phosphorylation might be increased in pervanadate-treated MEFs as a result of increased Src activity. This is unlikely because oncogenic Y 529 F Src lacks regulation by C-terminal tail phosphorylation. In addition, the observation that FAK activation loop phosphorylation was similar in both pervanadatetreated normal MEFs and oncogenic Src-expressing MEFs confirmed that phosphatase regulation of the C-terminal tail of Src was not an important factor in these experiments. We cannot rule out the possibility that phosphatase inhibition caused a decrease in the dephosphorylation of Tyr 416 , which could then have led to increased Src activity in both experimental cell models. However, it is clear that the methodology we have developed is able to accurately quantify changes in FAK activation loop phosphorylation.
The sum of activation loop forms after pervanadate treatment for normal and Y 529 FSrc-expressing MEFs were 0.855 (Ϯ 0.106) and 0.744 (Ϯ 0.081) pmol/pmol of total FAK, respectively. This indicated that a small portion of this region was modified to a form(s) undetected in our assay. The most likely explanation for this observation is that the hydrogen peroxide exposure during the pervanadate treatment resulted in some endogenous methionine sulfoxide formation of Met 571 within the activation loop segment tryptic peptide (YMEDSTYYK). Alternatively, it is possible that Tyr 570 became partially phosphorylated during the pervanadate treatment. It is noteworthy that normal Src-expressing MEFs were consistently found to have an almost 3-fold increase in total FAK/plate compared with Y 529 FSrc-expressing MEFs, whereas the total protein amounts per plate between the MEFs were equivalent.
To further investigate the relationship between Src activity and FAK activation loop phosphorylation, the small molecule AZD0530 was used to inhibit Src tyrosine kinases in cell culture. The recommended concentration of AZD0530 for inhibition of Src kinases in cell culture is 1 M. At this concentration, AZD0530 has been shown by Western blot to reduce the phosphorylation of Src substrates such paxillin (Hennequin et al., 2006; Jones et al., 2008) . AZD0530 is a potent inhibitor of FAK phosphorylation in vitro. However, it is a poor inhibitor of a number of other tyrosine-and serine/ threonine protein kinases (Hennequin et al., 2006) . Furthermore, the specificity and potency of AZD0530 toward Src compares very favorably with other inhibitors such as the pyrazolo [3,4-d] inib, and bosutinib (Hanke et al., 1996; Missbach et al., 1999; Serrels et al., 2006; Vultur et al., 2008 (Figs. 5 and 6 ), the amounts of unmodified and pTyr 576 -FAK forms were slightly increased. However, the sum of FAK activation loop forms for Src inhibited and pervanadatetreated transformed fibroblasts was in agreement with calculated amounts of the control peptide. This suggests that oncogenic Y 529 FSrc expression can cause further post-translational modifications to FAK's activation loop domain during pervanadate treatment and that these additional modifications are inhibited by 1 M AZD0530 pretreatment.
Src inhibitors will be targeted to cancers in which elevated Src activity is driving disease progression; therefore, the Src-transformed MEF model was chosen to conduct doseresponse experiments. More importantly, pTyr 576 /pTyr 577 -FAK was found to contribute only 6.0% to the total FAK in MEFs expressing normal Src, compared with 23.0% in oncogenic Src expressing MEFs. This limited the possible observable response to Src inhibition in the normal MEFs. A doseresponse curve to the Src inhibitor AZD0530 conducted in cell culture showed a similar trend (Fig. 7C) to that observed in vitro (Fig. 2C) , although the dose-response was shifted to the right by more than an order of magnitude. In comparison with in vitro Src inhibition, which showed a decrease in the amount of pTyr 576 /pTyr 577 -FAK with a drug concentration as low as 0.1 M, a decrease in pTyr 576 /pTyr 577 -FAK was not observed in Src-transformed fibroblasts until the cells had been treated with 1 M concentration of the drug (Fig. 7C) . A reduction of 50% in bis-phosphorylation of Tyr 576 /Tyr 577 -FAK was calculated to occur at 2.12 M AZD0530 (IC 50 value). Inhibition of paxillin (a substrate for Src phosphorylation at focal adhesions) phosphorylation by 70% was observed with 1 M AZD0530 when studies were conducted in the human lung tumor cell line (A549 non-small-cell lung cancer) using Western blot analysis (Hennequin et al., 2006) . Therefore, these previous experiments showed a similar trend to those we have obtained using bis-phosphorylation of FAK as a biomarker of cellular Src activity.
In summary, our new stable isotope dilution LC-MRM/MS assay showed that the Src inhibitor AZD0530 caused inhibition of pTyr 576 /pTyr 577 -FAK formation in a dose-dependent manner (Figs. 2B and 7B) . From these data, it was possible to determine AZD0530 IC 50 values for Src inhibition both in vitro (Fig. 2C ) and in cell culture (Fig. 7C ). There was a substantial difference in the ability of AZD0530 to inhibit Src that was constitutively activated in a cellular context (IC 50 ϭ 2.12 M) compared with the isolated enzyme (IC 50 ϭ 0.14 M). This suggests that higher concentrations of Src inhibitors such as AZD0530 might be required for in vivo efficacy than has been considered previously (Jones et al., 2008) . Results from the present study can be considered as the proof-of-concept for using FAK phosphorylation as a biomarker to determine the efficacy of Src inhibition in vivo. The increased accuracy and specificity that can be obtained by quantitative stable isotope dilution LC-MRM/MS methodology to quantify FAK phosphorylation offers significant advantages over current immunochemical approaches. Furthermore, elaboration of this methodology to other kinase targets will make it possible to rigorously assess the efficacy and specificity of novel targeted kinase inhibitors that are developed in the future.
